Do Lungs Grow Back After Surgery?

Lungs do not regrow in the way most people imagine. You will not sprout a brand-new lobe to replace one removed by a surgeon. But the remaining lung tissue can partially compensate for what was lost, expanding in volume and, under certain conditions, generating new gas-exchanging air sacs. How much compensation happens depends on your age, how much lung was removed, and factors researchers are still working to understand. The process is real, well-documented in animal studies, and increasingly supported by human evidence, but it falls well short of full regeneration.

What Compensatory Lung Growth Actually Means

Researchers draw a sharp line between genuine compensatory lung growth and mere inflation. When a lobe is removed, the remaining lung tissue shifts to fill the empty space in the chest cavity. Some of that space-filling is just the existing tissue stretching out or the chest wall adjusting. That is not growth. Compensatory lung growth specifically refers to the creation of new functioning tissue, including new alveoli (the tiny air sacs where oxygen enters the blood) and new blood vessels to serve them. Increases in air content, capillary congestion, or rearrangement of existing structures without new functional tissue do not count.¹

This distinction matters because it explains why some patients recover breathing capacity impressively after surgery while others plateau. Simple inflation of existing tissue helps fill the chest, but only genuine new tissue formation restores gas exchange toward its original level.

The Human Case That Changed the Conversation

For a long time, the prevailing view was that adult human lungs simply could not grow new tissue. Animal studies in mice and dogs showed robust compensatory growth, but direct evidence in adult humans was thin. That changed with a landmark case published in the New England Journal of Medicine. A 33-year-old woman had her entire right lung removed in 1995 to treat a lung cancer. As expected, her vital capacity dropped sharply. But over the following 15 years, it gradually climbed back up. Serial CT scans showed her remaining left lung progressively enlarging with increasing tissue density. Specialized MRI imaging with hyperpolarized helium-3 gas indicated that the regrowth involved an increase in the number of alveoli rather than just the enlargement of existing ones, though the new alveoli were shallower than those in a normal lung.²

This was a single patient, and researchers are cautious about generalizing from one case. But it provided the first direct imaging evidence that an adult human lung can form new alveoli after surgery, not just puff up existing ones. The timeline is also striking: the regrowth unfolded over years, not weeks. If you are expecting rapid recovery to full baseline capacity, the biology does not work that way.

How the Remaining Lobes Respond After Lobectomy

Most lung surgeries today remove a single lobe rather than an entire lung. A retrospective study tracking volume changes in remaining lobes after lobectomy found that total lung volume dropped by about 20% at one month after surgery, but the deficit narrowed to roughly 9% at six months and about 6% at twelve months. Individually, most remaining lobes actually exceeded their pre-surgery volumes. The compensation was stronger in lobes on the same side as the resection than on the opposite side, and inferior lobes (those lower in the chest) compensated more than superior ones.³

Volume recovery, though, is not the same as full functional recovery. These measurements tracked physical expansion of the remaining lobes. Whether that expansion reflects true new tissue formation or primarily inflation and remodeling varies by patient and is hard to distinguish on standard imaging.

The Gap Between Volume and Function

Breathing tests tell a different story than volume measurements. A study of pulmonary function after resection found that six months out, patients who had a single lobe removed still showed deficits of about 7% in forced vital capacity and 9% in the amount of air they could forcefully exhale in one second, compared with their pre-surgery values. For patients who lost an entire lung, those deficits were far larger: roughly 36% for vital capacity and 34% for forced expiratory volume. Peak exercise capacity dropped about 20% after pneumonectomy but was relatively preserved after lobectomy.⁴

The practical takeaway is that most people who lose a single lobe can return to a fairly normal level of activity. The remaining lung tissue compensates enough that everyday tasks feel manageable, even if formal lung-function numbers never return to their original levels. People who lose an entire lung face a larger challenge, but long-term survivors generally adjust to living with one lung and can lead fulfilling lives.⁵

Why Children Recover Better Than Adults

Age is the single biggest factor in how vigorously the lung compensates after surgery. Children, especially young children, have lungs that are still actively adding alveoli as part of normal development. When tissue is removed during this growth window, the remaining lung can ramp up that ongoing process. Growth through multiplication of alveoli appears to be an important mechanism during the first years of life, and surgical outcomes in the pediatric population generally reflect this capacity.⁶

A systematic review of pulmonary function after lobectomy in children confirmed that while human lungs have some compensatory growth capacity at any age, children have a distinctly stronger ability.⁷ Animal data sharpens this picture further. In young dogs, removing less than 45% of total lung tissue prompts vigorous alveolar regeneration that can restore alveolar numbers close to those of unoperated animals. In fully mature dogs, a much larger stimulus, removing 55% or more, is needed to trigger a weaker and incomplete response.⁸

For adults considering surgery, the message is that some compensation will happen, but it will be less dramatic than what occurs in a toddler’s lungs and will take longer to manifest.

What Triggers the Remaining Lung to Grow

When a lobe or an entire lung is removed, the remaining tissue is suddenly doing the same breathing work with less surface area. Each breath stretches it more than before. That mechanical stretch turns out to be the key signal. Computational models of mouse lungs after pneumonectomy showed that the stretch was not uniform. It was patchy and concentrated in subpleural regions near the diaphragm and at the top of the lobe. In these hot spots, tissue stretching during a single breath was two to four times greater than normal, with some regions experiencing a threefold increase in shear strain.⁹

These regions of exaggerated stretch line up with where new growth has been observed in previous studies. The cyclic expansion and contraction of each breath appears to act as a mechanical alarm system, telling the lung’s cells that demand is outpacing supply. That signal triggers a cascade of cellular events, including the proliferation of blood vessels. Immunohistochemistry in these same subpleural regions shows increased cell density and higher levels of growth factors involved in blood vessel formation.¹⁰

The Cells That Build New Alveoli

The lung’s gas-exchanging surface is lined by two types of cells. Type 1 cells are thin and flat, covering most of the alveolar surface for gas exchange. Type 2 cells (AT2 cells) are smaller and cube-shaped, and they produce surfactant, the substance that keeps alveoli from collapsing. AT2 cells also serve as the lung’s resident stem cells. When the lung is damaged or tissue is removed, AT2 cells can proliferate and then differentiate into the type 1 cells needed to rebuild the gas-exchange surface. Lineage-tracing experiments in mice have confirmed that individual AT2 cells can give rise to structures containing both cell types, essentially rebuilding functional alveoli from scratch.¹¹

This is encouraging but comes with limits. The process is slower than liver regeneration and does not always produce structurally perfect alveoli, as seen in the NEJM case where the new alveoli were shallower than normal. Researchers are still working out what controls how far the process goes before it stalls.

Genetics of Lung Regrowth

Gene-expression studies comparing post-surgical lung growth in mice with normal post-natal lung development found substantial overlap. Fifty-eight genes were active in both settings, with 40 of them changing in the same direction. The most consistently upregulated genes coded for structural proteins like collagen, elastin, and fibrillin-1, the scaffolding materials needed to physically build new alveolar walls.¹²

A specific transcription factor called FOXF1 has emerged as a key regulator. Mice with reduced FOXF1 activity showed impaired lung regeneration after partial pneumonectomy. FOXF1 directly controls genes involved in remodeling the extracellular matrix and in cell-cycle progression, two processes essential for building new tissue. Without adequate FOXF1 activity, the lung’s regrowth program stalls.¹³ This kind of finding matters because it suggests that individual genetic variation could partly explain why some people’s lungs compensate better than others after the same surgery.

How Lung Compensation Compares to Liver Regeneration

People often hear that the liver can “grow back” and wonder whether the lung can do the same thing. The comparison is informative but imperfect. In both organs, removing a large portion triggers widespread cell proliferation in the remaining tissue, and the regrowth is driven mainly by the existing mature cells rather than by a specialized stem-cell niche.¹⁴ Both organs also rely on signals from blood vessels to coordinate the regrowth process.¹⁵

The differences are what stand out, though. The liver can restore its original mass within weeks. The lung’s compensatory process unfolds over months to years and typically does not restore the original number of alveoli. The lung, liver, and pancreas all fall into a category scientists describe as having a “facultative” regenerative response: they do not constantly turn over cells the way skin or the gut lining does, but they can mount a robust proliferative response when damaged.¹⁶ The lung sits toward the slower, less complete end of that spectrum compared with the liver.

Animal Studies Fill In the Details

Much of what we know about the cellular mechanics of lung regrowth comes from mouse pneumonectomy models. In adult mice, removing the entire left lung triggers the right lung to restore its total gas-exchange surface area within about three weeks. Stereological analysis (precise counting of structures in tissue slices) showed that the number of alveoli in the remaining lung increased significantly by day 20, confirming that new alveoli were being formed, not just old ones expanding. However, the new alveoli accounted for only about 49% of those lost with the removed lung. The rest of the volume recovery came from enlargement of existing alveoli.¹⁷

Separate work confirmed that this process fully restored the body-mass-specific alveolar surface area in adult mice, meaning the total gas-exchange surface per unit of body weight returned to normal even though the alveolar count did not fully recover.¹⁸ The implication is that functional compensation can be substantial even when the structural rebuilding is incomplete, because larger alveoli still exchange gas, just less efficiently per unit of volume.

Rehabilitation Makes a Measurable Difference

Whatever the biology does on its own, structured pulmonary rehabilitation speeds recovery and improves quality of life after lung surgery. Rehabilitation programs that combine exercise training, breathing exercises, and psychological support have demonstrated benefits across multiple outcomes. Patients who went through rehabilitation after lung resection walked significantly farther on the six-minute walk test, reported less breathlessness, and had lower anxiety scores compared with a control group that did not receive rehabilitation.¹⁹

These programs also improve formal lung-function measures and exercise tolerance in patients with concurrent chronic obstructive pulmonary disease.²⁰ Pulmonary rehabilitation is now considered a standard component of care for lung-cancer patients who have had a lobectomy or more extensive resection, with documented improvements in pulmonary function, nutritional status, and overall quality of life.²¹

If you or someone you know is facing lung surgery, asking the surgical team about a post-operative rehabilitation plan is one of the most practical steps you can take. The biology of compensatory growth operates on its own timeline, but rehabilitation helps you make the most of whatever tissue you have while that process unfolds.

How Surgical Approach Affects Early Recovery

The type of surgery matters for how quickly you bounce back, even if it does not change the ultimate biological capacity for regrowth. Video-assisted thoracoscopic surgery (VATS), which uses small incisions and a camera, causes less disruption to the chest wall than a traditional open thoracotomy. A study comparing ribcage movement during exercise after each approach found that patients who had VATS restored normal chest-wall expansion faster. One month after surgery, VATS patients maintained their tidal volume during exercise by recruiting compensatory chest-wall motion, while thoracotomy patients showed reduced ribcage expansion and relied more on abdominal breathing. By a few months out, chest-wall function in the VATS group was essentially back to normal.²²

A meta-analysis of randomized trials also found that VATS produced modest but statistically significant improvements in early post-operative lung-function measurements compared with thoracotomy.²³ The long-term compensatory growth process probably plays out similarly regardless of surgical technique, but minimally invasive surgery gives you a head start by preserving chest-wall mechanics.

Emerging Research on Accelerating Regrowth

The fact that the lung retains some regenerative capacity has prompted researchers to look for ways to amplify it. Stem-cell therapies and molecular growth factors are being tested in animal models, particularly for conditions like emphysema where alveolar destruction is widespread and the lung’s natural repair mechanisms have failed. Both cell-based and drug-based approaches have shown promising results in animal models, though none have yet crossed the threshold into standard clinical use for humans.²⁴

The genetic findings around transcription factors like FOXF1 and the structural proteins like elastin and collagen that underpin alveolar wall construction offer potential drug targets. If scientists can identify compounds that boost these pathways safely, it could become possible to push the adult lung’s modest compensatory program toward something closer to the vigorous regrowth seen in children or young animals. That prospect is still years away from the clinic, but the biological plausibility is there, and the pace of research has accelerated considerably since the first direct evidence of adult human lung growth appeared just over a decade ago.